Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
The future of telehealth ketamine regulations depends largely on how the Drug Enforcement Administration (DEA) finalizes its special registration rule for telemedicine prescribing of controlled substances, a requirement Congress created in the SUPPORT for Patients and Communities Act of 2018. The COVID-era exemptions that currently let clinicians prescribe ketamine after a video visit, without an in-person exam, are temporary. A permanent framework is still being written, and it will determine whether today's telehealth ketamine model continues largely unchanged, gets restricted, or gets rebuilt around a more heavily regulated system. Below is a walk-through of the regulatory signals, from DEA rulemaking to state-level trends, that point toward where the rules are headed.
Quick Answer
The future of telehealth ketamine regulations will likely center on a DEA special registration process that lets clinicians continue prescribing Schedule III-V substances like ketamine through telemedicine, provided they verify patient identity, check state prescription drug monitoring programs (PDMPs), and meet new record-keeping standards. Current COVID-era telehealth flexibilities remain in effect while the DEA finalizes this permanent rule. Exact prescription limits and whether an in-person visit will eventually be required for continuation prescriptions are still undecided.
Every proposal for permanent telehealth controlled substance rules has to balance two competing priorities.
Access: Telehealth prescribing, including for ketamine, expands mental health treatment access for patients who cannot easily reach an in-person provider. Rural patients, patients with disabilities, patients without transportation, and patients whose work schedules make clinic visits difficult all rely on this access. Overly restrictive permanent rules could eliminate it.
Accountability: Controlled substances carry misuse and diversion risks, and remote prescribing without an in-person exam limits how much a clinician can assess certain risk factors. Without safeguards, telehealth prescribing could become a channel for inappropriate controlled substance use.
The final rules will show which of these two concerns the DEA weighs more heavily.
What the DEA's Permanent Framework Is Likely to Include
- A separate, more permissive registration category for non-narcotic Schedule III-V drugs like ketamine, compared to Schedule II opioids
- Mandatory identity verification through a government-issued ID before prescribing
- Formalized PDMP checks before every controlled substance prescription
- Enhanced record-keeping requirements documenting compliance with the new framework
What Remains Undecided
The DEA has not finalized prescription quantity limits, whether continuation prescriptions will eventually require an in-person visit, or how costly and complex the special registration process will be for smaller telehealth platforms. These details, not the broad framework, will determine whether the current telehealth ketamine model stays practical for patients and providers.
Congress has repeatedly extended COVID-era telehealth flexibilities for Medicare reimbursement, and there is bipartisan support for making some of them permanent. Medicare telehealth policy and DEA prescribing rules are governed separately, but Congressional intent to preserve telehealth access still shapes how the DEA approaches its rulemaking.
The SUPPORT Act, which originally mandated the DEA special registration in 2018, has taken years longer to implement than lawmakers intended. Congress has grown frustrated with the pace of DEA rulemaking and may attach specific deadlines to future legislation.
States are moving in parallel with federal rulemaking. Oregon, Colorado, California, and other states have enacted or are developing regulated frameworks for psychedelic-assisted therapy, primarily aimed at psilocybin. These programs build regulatory infrastructure and public familiarity that may indirectly benefit ketamine therapy.
Many states are also updating telehealth practice standards to create clearer rules for interstate and chronic disease management, changes that generally support the existing telehealth ketamine model. Our state-by-state regulations guide covers where individual states currently stand, and our telehealth law updates track recent changes.
Increased enforcement of mental health parity laws could eventually reach ketamine therapy. If treatment-resistant depression care must be covered under the same terms as other medical treatments, insurance coverage could expand significantly, changing the economics of the market. Our insurance coverage guide covers the current coverage landscape.
Improving remote monitoring technology, including wearable heart rate and blood pressure monitors and video-based vital sign checks, may let telehealth platforms offer more thorough safety monitoring. That could ease one of the main criticisms of at-home ketamine therapy and expand the range of patients who can safely be treated remotely.
Electronic prescribing of controlled substances (EPCS), a system that transmits controlled substance prescriptions directly and securely to a pharmacy, is increasingly standard and may become a formal requirement. Platforms already using EPCS are better positioned for regulatory changes.
Some platforms are also testing AI-assisted clinical decision support to help identify appropriate candidates and flag safety concerns. Used carefully, these tools could improve outcomes in ways that support the case for continued telehealth access.
The Most Likely Outcome
Based on current signals, the most probable permanent framework allows telemedicine prescribing of Schedule III-V substances like ketamine through a streamlined registration, requires identity verification and PDMP compliance, and adds documentation requirements, without requiring an in-person visit for initial prescriptions. It may require an in-person evaluation after an initial telehealth-only period for continuation prescriptions. This would preserve most of today's telehealth ketamine model while adding new accountability safeguards. The open question is whether the administrative burden of the new registration process is manageable for smaller platforms.
The exemptions currently allowing telehealth ketamine access remain in effect. For a full breakdown of the legal framework currently in place, see our telehealth legality overview.
Action Checklist
- Continue accessing care through your current platform; the COVID-era exemptions remain in effect
- Monitor communications from your provider about regulatory changes
- Build a relationship with a local, in-person provider as a backup in case telehealth access is disrupted
- Follow DEA rulemaking updates directly at DEA.gov
StatPearls: Ketamine, a clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications.
PubChem: Ketamine Compound Summary, an NCBI chemical database entry with molecular data, pharmacokinetics, and bioactivity profiles.
MedlinePlus: Ketamine, National Library of Medicine consumer drug information covering uses, administration, and precautions.
HHS: Telehealth, the U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources.
SAMHSA: National Helpline, a free, confidential treatment referral and information service from the Substance Abuse and Mental Health Services Administration.
Learn More
Have questions about how upcoming regulatory changes could affect your access to telehealth ketamine treatment?
Share
Related Reading
Have a question about this topic?
Use the contact page when you need to send feedback, request a correction, or ask about the resource.